[123] showed that the tyrosine kinase inhibitor (TKI) nintedanib promotes entosis via the CDC42/ROCK pathway, and combining abiraterone with the Plk1 inhibitor onvansertib induced mitotic cancer cell death and entosis in abiraterone‐resistant metastatic CRPC mouse models independently of AR signaling. This evidence concerns the gene AR and cancer.